{
    "nct_id": "NCT04832854",
    "official_title": "A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified\n* Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC\n* Any prior therapy for lung cancer\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Active tuberculosis\n* Significant cardiovascular disease\n* NSCLC with an activating EGFR mutation or ALK fusion oncogene\n* Known c-ros oncogene 1 (ROS1) rearrangement\n* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with negligible risk of metastasis or death\n* Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety\n* Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents\n* Treatment with systemic immunosuppressive medication\n* Pregnancy or breastfeeding",
    "miscellaneous_criteria": "Key inclusion criteria:\n\n* Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology\n* Eligible for R0 resection with curative intent at the time of screening\n* Adequate pulmonary function to be eligible for surgical resection with curative intent\n* Eligible to receive a platinum-based chemotherapy regimen\n* Measurable disease, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Availability of a representative tumor specimen that is suitable for determination of PD-L1 status\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Normal life expectancy, excluding lung cancer mortality risk\n* Adequate hematologic and end-organ function\n* Negative human immunodeficiency virus (HIV) test at screening\n* Negative serology for active hepatitis B virus (HBV) and active hepatitis C virus (HCV) at screening\n\nKey"
}